BioSpace News Archive

Sleep disorder, also known as somnipathy, is a medical condition wherein a disorder is generated in the sleep pattern.

The process that helps separate suspended particles from a medium by passing them through a membrane is known as filtration.

The growing need for a safe and low-risk work space for the medical workforce is driving the global medical pendant systems market.

The demand within the global hormonal contraceptives market is rising at a stellar pace in recent times.

High performance liquid chromatography is one of the techniques used to separate, quantitate, and identify components in the given mixture.

Inventive technologies and cutting-edge research have led to the development of several innovative magnetic resonance imaging equipment, helping patients live healthier and longer lives.

Increasing the dose frequency of lanreotidefrom monthly to bi-monthly achieved a progression-free survival of 8.3 months in patients with progressive midgut neuroendocrine tumors (NETs) and 5.6 months in patients with progressive pancreatic NETs

Autolus Therapeutics plc announced new data highlighting progress on AUTO3, the company’s CAR T cell therapy being investigated in the ALEXANDER study, a Phase 1/2 clinical trial in relapsed/refractory diffuse large B cell lymphoma, during the European Society for Medical Oncology Virtual Congress 2020, beginning 18 September.

Regeneron Pharmaceuticals, Inc. and Sanofi announced the presentation of positive results from the pivotal Phase 2 trial for the PD-1 inhibitor Libtayo® in patients with locally advanced basal cell carcinoma who had progressed on or were intolerant to hedgehog inhibitor therapy.

Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing personalized yet off the shelf immunotherapies for cancer and infectious diseases, announced today results from the Phase 1/2 clinical trial evaluating the safety, efficacy, and immunogenicity of SNS‑301, a first-in-class bio-engineered, inactivated bacteriophage, in patients with Locally Advanced Unresectable or Metastatic/Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)